Source: Gladstone Institutes
Date: October 9, 2008
Summary:
Scientists in the lab of Shinya Yamanaka MD, PhD, of Kyoto University and the Gladstone Institute of Cardiovascular Disease (GICD) have taken another step forward in improving the possibilities for the practical application of induced pluripotent stem (iPS) cell technology. have eliminated the need for a viral vector in the stem cell reprogramming process In a report in Science, they showed the ability to reprogram adult cells into iPS cells without viral integration into the genome which lays to rest concerns that the reprogramming event might be dependent upon viral integration into specific genomic loci that could mediate the genetic switch.
